Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Author(s): Bojan Mitrovic, Zoran Gluvic*, Djuro Macut, Milan Obradovic, Emina Sudar-Milovanovic, Sanja Soskic, Dragan Stajic and Esma R. Isenovic

DOI: 10.2174/1871530321666210225110140

DownloadDownload PDF Flyer Cite As
Effects of Metformin-Single Therapy on the Level of Inflammatory Markers in Serum of Non-Obese T2DM Patients with NAFLD

Page: [117 - 124] Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Background and Objectives: Non-alcoholic fatty liver disease (NAFLD) is associated with inflammation and subsequent increase in cardiovascular risk. Because of its widespread presence and distribution, invasive diagnostic procedures (i.e., liver biopsy) are reserved for a limited number of subjects. With liver ultrasound, Fatty liver index (FLI) and fibrosis-4 (FIB-4) scores non-invasively assess liver steatosis and fibrosis. We aimed to evaluate the changes in inflammatory markers and FLI/FIB-4 scores in non-obese metformin-treated type 2 diabetes patients (T2DM) with NAFLD.

Methods: All subjects underwent abdominal ultrasound aiming for NAFLD stratification (grade 1 to 3 according to its severity). Metabolic parameters (morning glycaemia, HbA1C, lipids, liver function tests), serum inflammatory markers (C-reactive protein, ferritin, and nitric oxide) and FLI/- FIB-4 were calculated.

Results: FLI score and ultrasound NAFLD grades were found to correlate (p<0.05). We observed a significant correlation between the levels of ferritin and C-reactive protein (CRP) (p<0.05), and the FLI (p<0.05). Body weight (BW) (p<0.05), waist circumference (WC) (p<0.05), the levels of HbA1c (p<0.05), transferrin (p<0.05), insulin (p<0.05), and FLI score (p<0.05) significantly differed between groups as defined by the severity of NAFLD.

Conclusion: This pilot study suggests that the serum inflammatory markers at the average normal values point to the sufficiency of metformin-single therapy in inflammation control in non-obese T2DM patients with NAFLD.

Keywords: Diabetes, metformin, non-alcoholic fatty liver disease, inflammation, liver ultrasound, FLI/FIB-4 scores.

Graphical Abstract

[1]
Bellentani, S. The epidemiology of non-alcoholic fatty liver disease. Liver Int., 2017, 37(Suppl. 1), 81-84.
[http://dx.doi.org/10.1111/liv.13299] [PMID: 28052624]
[2]
Jennings, J.; Faselis, C.; Yao, M.D. NAFLD-NASH: An Under-Recognized Epidemic. Curr. Vasc. Pharmacol., 2018, 16(3), 209-213.
[http://dx.doi.org/10.2174/1570161115666170622074007] [PMID: 28676024]
[3]
Younossi, Z.M.; Koenig, A.B.; Abdelatif, D.; Fazel, Y.; Henry, L.; Wymer, M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64(1), 73-84.
[http://dx.doi.org/10.1002/hep.28431] [PMID: 26707365]
[4]
Katsiki, N.; Mikhailidis, D.P.; Mantzoros, C.S. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism, 2016, 65(8), 1109-1123.
[http://dx.doi.org/10.1016/j.metabol.2016.05.003] [PMID: 27237577]
[5]
Fotbolcu, H.; Zorlu, E. Nonalcoholic fatty liver disease as a multi-systemic disease. World J. Gastroenterol., 2016, 22(16), 4079-4090.
[http://dx.doi.org/10.3748/wjg.v22.i16.4079] [PMID: 27122660]
[6]
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 2016, 64(6), 1388-1402.
[http://dx.doi.org/10.1016/j.jhep.2015.11.004] [PMID: 27062661]
[7]
Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turner, R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985, 28(7), 412-419.
[http://dx.doi.org/10.1007/BF00280883] [PMID: 3899825]
[8]
Pais, R.; Charlotte, F.; Fedchuk, L.; Bedossa, P.; Lebray, P.; Poynard, T.; Ratziu, V. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J. Hepatol., 2013, 59(3), 550-556.
[http://dx.doi.org/10.1016/j.jhep.2013.04.027] [PMID: 23665288]
[9]
Wieckowska, A.; Zein, N.N.; Yerian, L.M.; Lopez, A.R.; McCullough, A.J.; Feldstein, A.E. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology, 2006, 44(1), 27-33.
[http://dx.doi.org/10.1002/hep.21223] [PMID: 16799979]
[10]
Manousou, P.; Kalambokis, G.; Grillo, F.; Watkins, J.; Xirouchakis, E.; Pleguezuelo, M.; Leandro, G.; Arvaniti, V.; Germani, G.; Patch, D.; Calvaruso, V.; Mikhailidis, D.P.; Dhillon, A.P.; Burroughs, A.K. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int., 2011, 31(5), 730-739.
[http://dx.doi.org/10.1111/j.1478-3231.2011.02488.x] [PMID: 21457446]
[11]
Abenavoli, L.; Milic, N.; Di Renzo, L.; Preveden, T.; Medić-Stojanoska, M.; De Lorenzo, A. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J. Gastroenterol., 2016, 22(31), 7006-7016.
[http://dx.doi.org/10.3748/wjg.v22.i31.7006] [PMID: 27610012]
[12]
Abenavoli, L.; Peta, V. Role of adipokines and cytokines in non-alcoholic fatty liver disease. Rev. Recent Clin. Trials, 2014, 9(3), 134-140.
[http://dx.doi.org/10.2174/1574887109666141216102458] [PMID: 25514909]
[13]
Katsiki, N.; Athyros, V.G.; Karagiannis, A.; Wierzbicki, A.S.; Mikhailidis, D.P. Should we expand the concept of coronary heart disease equivalents? Curr. Opin. Cardiol., 2014, 29(4), 389-395.
[http://dx.doi.org/10.1097/HCO.0000000000000068] [PMID: 25029454]
[14]
Athyros, V.G.; Polyzos, S.A.; Kountouras, J.; Katsiki, N.; Anagnostis, P.; Doumas, M.; Mantzoros, C.S. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Curr. Vasc. Pharmacol., 2020, 18(2), 172-181.
[http://dx.doi.org/10.2174/1570161117666190405164313] [PMID: 30961499]
[15]
Targher, G.; Bertolini, L.; Padovani, R.; Rodella, S.; Tessari, R.; Zenari, L.; Day, C.; Arcaro, G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care, 2007, 30(5), 1212-1218.
[http://dx.doi.org/10.2337/dc06-2247] [PMID: 17277038]
[16]
Giorda, C.; Forlani, G.; Manti, R.; Mazzella, N.; De Cosmo, S.; Rossi, M.C.; Nicolucci, A.; Russo, G.; Di Bartolo, P.; Ceriello, A.; Guida, P. Occurrence over time and regression of nonalcoholic fatty liver disease in type 2 diabetes. Diabetes Metab. Res. Rev., 2017, 33(4)
[http://dx.doi.org/10.1002/dmrr.2878] [PMID: 28032449]
[17]
Klisic, A.; Isakovic, A.; Kocic, G.; Kavaric, N.; Jovanovic, M.; Zvrko, E.; Skerovic, V.; Ninic, A. Relationship between oxidative stress, inflammation and dyslipidemia with fatty liver index in patients with type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes, 2018, 126(6), 371-378.
[http://dx.doi.org/10.1055/s-0043-118667] [PMID: 28895641]
[18]
Wieckowska, A.; Feldstein, A.E. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin. Liver Dis., 2008, 28(4), 386-395.
[http://dx.doi.org/10.1055/s-0028-1091983] [PMID: 18956295]
[19]
Martínez, S.M.; Crespo, G.; Navasa, M.; Forns, X. Noninvasive assessment of liver fibrosis. Hepatology, 2011, 53(1), 325-335.
[http://dx.doi.org/10.1002/hep.24013] [PMID: 21254180]
[20]
Bedogni, G.; Bellentani, S.; Miglioli, L.; Masutti, F.; Passalacqua, M.; Castiglione, A.; Tiribelli, C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol., 2006, 6, 33-33.
[http://dx.doi.org/10.1186/1471-230X-6-33]
[21]
Sterling, R.K.; Lissen, E.; Clumeck, N.; Sola, R.; Correa, M.C.; Montaner, J.; S Sulkowski, M.; Torriani, F.J.; Dieterich, D.T.; Thomas, D.L.; Messinger, D.; Nelson, M. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology, 2006, 43(6), 1317-1325.
[http://dx.doi.org/10.1002/hep.21178] [PMID: 16729309]
[22]
Katsiki, N.; Perez-Martinez, P.; Anagnostis, P.; Mikhailidis, D.P.; Karagiannis, A. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome? Curr. Vasc. Pharmacol., 2018, 16(3), 219-227.
[http://dx.doi.org/10.2174/1570161115666170621075619] [PMID: 28669328]
[23]
Gluvic, Z.; Zaric, B.; Resanovic, I.; Obradovic, M.; Mitrovic, A.; Radak, D.; Isenovic, E.R. Link between Metabolic Syndrome and Insulin Resistance. Curr. Vasc. Pharmacol., 2017, 15(1), 30-39.
[http://dx.doi.org/10.2174/1570161114666161007164510] [PMID: 27748199]
[24]
Grundy, S.M.; Cleeman, J.I.; Daniels, S.R.; Donato, K.A.; Eckel, R.H.; Franklin, B.A.; Gordon, D.J.; Krauss, R.M.; Savage, P.J.; Smith, S.C.Jr.; Spertus, J.A.; Costa, F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 2005, 112(17), 2735-2752.
[http://dx.doi.org/10.1161/circulationaha.105.169404] [PMID: 16157765]
[25]
Abenavoli, L.; Boccuto, L.; Federico, A.; Dallio, M.; Loguercio, C.; Di Renzo, L.; De Lorenzo, A. Diet and non-alcoholic fatty liver disease: The Mediterranean way. Int. J. Environ. Res. Public Health, 2019, 16(17), E3011.
[http://dx.doi.org/10.3390/ijerph16173011] [PMID: 31438482]
[26]
Lundberg, J.O.; Gladwin, M.T.; Ahluwalia, A.; Benjamin, N.; Bryan, N.S.; Butler, A.; Cabrales, P.; Fago, A.; Feelisch, M.; Ford, P.C.; Freeman, B.A.; Frenneaux, M.; Friedman, J.; Kelm, M.; Kevil, C.G.; Kim-Shapiro, D.B.; Kozlov, A.V.; Lancaster, J.R., Jr; Lefer, D.J.; McColl, K.; McCurry, K.; Patel, R.P.; Petersson, J.; Rassaf, T.; Reutov, V.P.; Richter-Addo, G.B.; Schechter, A.; Shiva, S.; Tsuchiya, K.; van Faassen, E.E.; Webb, A.J.; Zuckerbraun, B.S.; Zweier, J.L.; Weitzberg, E. Nitrate and nitrite in biology, nutrition and therapeutics. Nat. Chem. Biol., 2009, 5(12), 865-869.
[http://dx.doi.org/10.1038/nchembio.260] [PMID: 19915529]
[27]
Gluvic, Z.M.; Sudar-Milovanovic, E.M.; Samardzic, V.S.; Obradovic, M.M.; Jevremovic, D.P.; Radenkovic, S.P.; Isenovic, E.R. Serum nitric oxide levels correlate with quality of life questionnaires scores of hypothyroid females. Med hypotheses., 2019, 131, 109299.
[http://dx.doi.org/10.1016/j.mehy.2019.109299]
[28]
Friedewald, W.T.; Levy, R.I.; Fredrickson, D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem., 1972, 18(6), 499-502.
[http://dx.doi.org/10.1093/clinchem/18.6.499] [PMID: 4337382]
[29]
Singh, D.; Das, C.J.; Baruah, M.P. Imaging of non alcoholic fatty liver disease: A road less travelled. Indian J. Endocrinol. Metab., 2013, 17(6), 990-995.
[http://dx.doi.org/10.4103/2230-8210.122606] [PMID: 24381873]
[30]
Younossi, Z.M.; Marchesini, G.; Pinto-Cortez, H.; Petta, S. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. Transplantation, 2019, 103(1), 22-27.
[http://dx.doi.org/10.1097/TP.0000000000002484] [PMID: 30335697]
[31]
Yki-Järvinen, H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol., 2014, 2(11), 901-910.
[http://dx.doi.org/10.1016/S2213-8587(14)70032-4] [PMID: 24731669]
[32]
Grgurevic, I.; Podrug, K.; Mikolasevic, I.; Kukla, M.; Madir, A.; Tsochatzis, E.A. Natural history of nonalcoholic fatty liver disease: implications for clinical practice and an individualized approach. Can J Gastroenterol Hepatol., 2020, 2020, 9181368.
[33]
Kwok, R.; Choi, K.C.; Wong, G.L.; Zhang, Y.; Chan, H.L.; Luk, A.O.; Shu, S.S.; Chan, A.W.; Yeung, M.W.; Chan, J.C.; Kong, A.P.; Wong, V.W. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut, 2016, 65(8), 1359-1368.
[http://dx.doi.org/10.1136/gutjnl-2015-309265] [PMID: 25873639]
[34]
Adams, L.A.; Harmsen, S.; St Sauver, J.L.; Charatcharoenwitthaya, P.; Enders, F.B.; Therneau, T.; Angulo, P. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am. J. Gastroenterol., 2010, 105(7), 1567-1573.
[http://dx.doi.org/10.1038/ajg.2010.18] [PMID: 20145609]
[35]
Hamed, A.E.; Elwan, N.; Naguib, M.; Elwakil, R.; Esmat, G.; El Kassas, M.; Abd-Elsalam, S.; Moussa, S. Diabetes Association with liver diseases: an overview for clinicians. Endocr. Metab. Immune Disord. Drug Targets, 2019, 19(3), 274-280.
[http://dx.doi.org/10.2174/1871530318666181116111945] [PMID: 30444204]
[36]
Hamed, A.E.; Elsahar, M.; Elwan, N.M.; El-Nakeep, S.; Naguib, M.; Soliman, H.H.; Aboubakr, A.A.; AbdelMaqsod, A.; Sedrak, H.; Assaad, S.N.; Elwakil, R.; Esmat, G.; Salh, S.; Mostafa, T.; Mogawer, S.; Sadek, S.E.; Saber, M.M.; Ezelarab, H.; Mahmoud, A.A.; Sultan, S.; El Kassas, M.; Kamal, E.; ElSayed, N.M.; Moussa, S. Managing diabetes and liver disease association: Practice guidelines from the Egyptian Association for the Study of Liver and Gastrointestinal Disease (EASLGD). Arab J. Gastroenterol., 2019, 20(1), 61-63.
[http://dx.doi.org/10.1016/j.ajg.2019.02.002] [PMID: 30852101]
[37]
Orsi, E.; Grancini, V.; Menini, S.; Aghemo, A.; Pugliese, G. Hepatogenous diabetes: Is it time to separate it from type 2 diabetes? Liver Int., 2017, 37(7), 950-962.
[http://dx.doi.org/10.1111/liv.13337] [PMID: 27943508]